| 摘要 |
Disclosed and claimed is the cardiotonic use of 1-R1-5-(3-R'-4-R''-phenyl)-6-R-2(1H)-pyridinones (II), where R1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl or hydrogen, and, R' and R'' are each hydrogen, amino or hydroxy, at least one of R' or R'' being other than hydrogen, or where R' is nitro when R'' is hydroxy, or pharmaceutically acceptable acid-addition salts thereof where at least one of R' and R'' is amino. Also disclosed and claimed are 1-R1-5-(3-R'-4-R''-phenyl)-6-R-2(1H)-pyridinones (I), where R1, R' and R'' are defined as above and R is lower-alkyl and acid-addition salts thereof where at least one of R' and R'' is amino. Also shown and claimed is the process which comprises reacting 1-R1-1,2-dihydro-2-oxo-5-(3-R'-4-R''-phenyl)-6-R-nicotinonitrile, where R1 and R are defined as above for II, R' is hydrogen, hydroxy, methoxy or amino and R'' is hydroxy, methoxy or hydrogen, preferably at least one of R' and R'' being methoxy, or where R' is nitro and R'' is hydrogen or methoxy, preferably methoxy, with 85% phosphoric acid to produce 1-R1-5-(3-R'-4-R''-phenyl)-6-R-2(1H)-pyridinone.
|
